We next asked whether luminal or IM cell state signatures derived from ERG+ GEMMs might distinguish between different clinical outcomes in ERG+ human patients with PCa by interrogating baseline tumor transcriptomes (bulk RNA-seq) in two widely studied cohorts. The gene discussed is ERG; the disease is posterior cortical atrophy.